Jefferies Downgrades Astria Therapeutics (ATXS) to Hold

Jefferies analyst Eun Yang downgraded Astria Therapeutics (NASDAQ: ATXS) from Buy to Hold with a price target of $13.00 (from $30.00).

For an analyst ratings summary and ratings history on Astria Therapeutics click here. For more ratings news on Astria Therapeutics click here.

Shares of Astria Therapeutics closed at $8.47 yesterday.

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities
• Rakus Co Ltd (3923:JP) PT Raised to JPY1,300 at Macquarie